BELL vs. RUA, SUN, MHC, MXCT, DEMG, NIOX, SN, EKF, CREO, and IUG
Should you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include RUA Life Sciences (RUA), Surgical Innovations Group (SUN), MyHealthChecked (MHC), MaxCyte (MXCT), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical devices" industry.
Belluscura vs. Its Competitors
Belluscura (LON:BELL) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.
In the previous week, Belluscura's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.
RUA Life Sciences has a net margin of -65.72% compared to Belluscura's net margin of -1,030.73%. RUA Life Sciences' return on equity of -26.38% beat Belluscura's return on equity.
RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.
6.3% of Belluscura shares are held by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are held by institutional investors. 56.3% of Belluscura shares are held by company insiders. Comparatively, 51.3% of RUA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Belluscura has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500.
Summary
RUA Life Sciences beats Belluscura on 9 of the 11 factors compared between the two stocks.
Get Belluscura News Delivered to You Automatically
Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Belluscura Competitors List
Related Companies and Tools
This page (LON:BELL) was last updated on 7/16/2025 by MarketBeat.com Staff